News ZyVersa Therapeutics, Inc.

Equities

ZVSA

US98987D3008

Market Closed - Nasdaq Other stock markets 04:30:01 2024-07-05 pm EDT			5-day change	1st Jan Change
3.666 ^USD	+1.55%		-2.50%	-59.27%

May. 15	ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 25	ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease	Mar. 18	CI
HC Wainwright Cuts Price Target on ZyVersa Therapeutics to $12 From $24, Maintains Buy Rating	Mar. 12	MT
ZyVersa Therapeutics, Inc. Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option	Feb. 22	CI
Jobs Data in Focus as Exchange-Traded Funds Advance, Equity Futures Mixed Pre-Bell Thursday	Dec. 07	MT
Top Premarket Decliners	Dec. 07	MT
ZyVersa Prices $5 Million Offering of Common Shares, Warrants	Dec. 07	MT
ZyVersa Therapeutics, Inc. Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100?s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways	Dec. 06	CI
Top Midday Decliners	Nov. 30	MT
ZyVersa Therapeutics Shares Fall Following Announcement of Reverse Stock Split, Increase in Authorized Common Shares	Nov. 30	MT
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock	Nov. 30	GL
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results	Nov. 14	GL
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model	Nov. 09	GL
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation	Nov. 06	GL
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection	Nov. 01	GL
ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection	Nov. 01	CI
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease	23-10-25	GL
ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease	23-10-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ZyVersa Therapeutics, Inc.

Equities

ZVSA

US98987D3008

Summary

Filters